Results 91 to 100 of about 22,516 (228)

Identification of a ferroptosis related genes signature and GDF15 contributing to a new perspective for the diagnosis of CRPC

Scientific Reports
Prostate cancer (PCa) is a highly prevalent malignancy among men. Castration-resistant prostate cancer (CRPC) is the main pathological type leading to the death of patients.
Yuanyuan Shao, Xiaoli Li, Jiaolong Liu, Zhongjian Qiu, Taijian Zhang, Nan Li, Jianmeng Hu, Fuding Lu, Zhiguo Zhu   +8 more
doaj   +1 more source

NRF2/xCT‐Mediated Antioxidant Adaptation Attenuates Apoptosis Induced by ASCT2 Inhibition in Prostate Cancer

Cancer Science, Volume 117, Issue 10, Page 2769-2789, October 2026.
ASCT2 inhibition induces ROS accumulation and activates NRF2‐dependent xCT upregulation in prostate cancer. This adaptive response partially supports residual cystine acquisition and glutathione synthesis, whereas combined ASCT2 and xCT inhibition disrupts redox compensation and predominantly promotes apoptotic cell death.
Jiaxing Wei, Yasutaka Yamada, Takaaki Tamura, Masahiro Sugiura, Xue Zhao, Meng Ni, Adilan Aierken, Tomokazu Sazuka, Yusuke Imamura, Shinichi Sakamoto   +9 more
wiley   +1 more source

SCOPE OF THE SUBORDINATE JUDICIARY UNDER SECTION 482 OF CRPC [PDF]

Section 482 of the Code of Criminal Procedure (CrPC) extends plenary powers to the High Courts to deal with any form of criminal matters. But whether these powers percolate down to the magistrates courts is a question because time and again these courts ...
Durga Khaitan
core  

Abstract 228: Identification of a novel biomarker to predict castration-resistant prostate cancer (CRPC) by the proteome analysis

, 2017
Prostate specific antigen (PSA) is useful for screening prostate cancer, while it has no reliable correlation with pathological malignancy of prostate cancer and is not a predictor for castration resistant prostate cancer (CRPC).
Norihisa Ohtake, Noriaki Arakawa, Hiroji Uemura, Yusuke Itoh, Masahiro Yao, Yasuhide Miyoshi, Shouhei Akiba, Takashi Kawahara   +7 more
core   +1 more source

Population Pharmacokinetics of Cabozantinib: Updated Analyses Including Data in Combination With Atezolizumab in Patients With Castration‐Resistant Prostate Cancer and Other Tumor Types

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Cabozantinib is a small‐molecule tyrosine kinase inhibitor approved for the treatment of various locally advanced or metastatic solid tumors. The phase 1b COSMIC‐021 study evaluated cabozantinib as a monotherapy or in combination with atezolizumab in patients with advanced solid tumors, including castration‐resistant prostate cancer (CRPC ...
Jason H. Williams, Hanbin Li, Ahmed A. Othman   +2 more
wiley   +1 more source

Mechanism of AR transactivation in CRPC cells: role of Nrf2, p65-Nrf1 and p120-Nrf1.

, 2014
In CRPC cells (e.g. C4-2B), despite ADT, residual androgens (e.g. DHT) increase nuclear p65-Nrf1 and simultaneously decrease both total Nrf2 and nuclear p120-Nrf1 levels.
Debasis Mondal (466034), Asim B. Abdel-Mageed (512681), Michelle A. Schultz (512676), Yiguo Zhang (512679), Amrita Datta (512678), Suresh C. Sikka (512680), Sharika S. Hagan (512677), Michael L. Freeman (164199)   +7 more
core   +1 more source

THE ROLE OF DOCETAXEL AS FIRST-LINE CHEMOTHERAPY ON PSA LEVEL AND QOL IN CRPC PATIENTS [PDF]

Objective: Prostate cancer is the second most common cancer in men and the fifth leading cause of death worldwide. 10-20% of cases can progress to a more aggressive stage called castration-resistant prostate cancer (CRPC) with a higher death rate ...
Nurhadi, Pradana, Seputra, Kurnia Penta, Satria, Hikmat   +2 more
core   +1 more source

Inactivation of ID4 promotes a CRPC Phenotype with Constitutive AR Activation through FKBP52.

, 2016
Castration-resistant prostate cancer (CRPC) is the emergence of prostate cancer cells that have adapted to the androgen-depleted environment of the prostate.
Hewa Bostanthirige, D., Gorantla, Y., Zou, J.., Joshi, J. B., Sharma, P., Nagapan, P., Patel, D., Morton, D. J.   +7 more
core   +2 more sources

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance

Frontiers in Endocrinology
Prostate cancer (PCa) is commonly occurred with high incidence in men worldwide, and many patients will be eventually suffered from the dilemma of castration-resistance with the time of disease progression.
Jingang Jian, Jingang Jian, Xin’an Wang, Jun Zhang, Chenchao Zhou, Xiaorui Hou, Xiaorui Hou, Yuhua Huang, Jianquan Hou, Jianquan Hou, Yuxin Lin, Yuxin Lin, Xuedong Wei   +12 more
doaj   +1 more source

Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer

Clinical and Translational Medicine
Background Cyclin‐dependent kinase 12 (CDK12)‐deficient prostate cancer defines a subtype of castration‐resistant prostate cancer (CRPC) with a poor prognosis.
Haozhe Zhang, Yi Zhou, Yating Feng, Wenli Hou, Yafei Chen, Zengzhen Xing, Yifan Zhang, Qiang Wei, Yu Yin, Ju Guo, Hailiang Hu   +10 more
doaj   +1 more source